Reviewing The Latest Treatments for Haemophilia

Mrs. Rani.B; Dr. S.K.Mohanasundari; Mrs. Rashmi Singh; Mrs. Neelam Vasishtha; Mrs. Vandana.N; Mrs. Nagamani. M

doi:10.36948/ijfmr.2024.v06i05.27443

Reviewing The Latest Treatments for Haemophilia

Author(s)	Mrs. Rani.B, Dr. S.K.Mohanasundari, Mrs. Rashmi Singh, Mrs. Neelam Vasishtha, Mrs. Vandana.N, Mrs. Nagamani. M
Country	India
Abstract	Abstract: Advancements in haemophilia treatment have been significant in the first 20 years of the 21st century. However, the progress started with the fractionation of plasma in 1946. The first concentrates were developed after discovering FVIII in frozen plasma cryoprecipitate and FIX in the supernatant in the early 1960s, leading to initial attempts at replacement therapy. Unfortunately, due to the lack of screening methods for viral pathogens, people with haemophilia (PWH) received contaminated concentrates, leading to infections with the hepatitis A virus, hepatitis C virus, and human immunodeficiency virus. Thankfully, by 1985, viral screening methods and virucidal techniques were developed, making concentrates safe. The introduction of chromatography steps with monoclonal antibodies in the production process led to increasingly pure products. However, the problem of immunogenicity of administered concentrates persists. The development of alloantibodies against FVIII in a significant percentage of PWH is a serious adverse effect of replacement therapy. The next major advancement came with cloning the F8 and F9 genes, which allowed the production of factor concentrates using recombinant DNA technology. The injected FVIII and FIX molecules have a relatively short circulating half-life in the plasma of people with haemophilia A and B, approximately 12 and 18 hours, respectively. Methods such as conjugating the factor molecule with fragment crystallizable of IgG1, albumin, or adding polyethylene glycol have been applied to prolong the plasma half-life and extend the interval between injections, especially for risk. The next frontier in haemophilia therapy is the development of durable and potentially curative treatments, such as gene addition therapy. Experiments in haemophilia B have shown promising long-lasting responses. However, the results of gene therapy for haemophilia A have not been as remarkable, and the durability of the treatment is yet to be demonstrated. The long-term safety, predictability, durability, and efficacy of gene therapy for haemophilia A and B remain open questions. Currently, only healthy adult PWH has been enrolled in gene therapy clinical trials, and further studies are needed before gene therapy can be widely applied to children and those with pre-existing antibodies against the delivery vector.
Keywords	Keywords: replacement therapy, adverse events, pharmacokinetics, extended half-life concentrates, non-replacement therapy, gene therapy
Field	Medical / Pharmacy
Published In	Volume 6, Issue 5, September-October 2024
Published On	2024-09-19
Cite This	Reviewing The Latest Treatments for Haemophilia - Mrs. Rani.B, Dr. S.K.Mohanasundari, Mrs. Rashmi Singh, Mrs. Neelam Vasishtha, Mrs. Vandana.N, Mrs. Nagamani. M - IJFMR Volume 6, Issue 5, September-October 2024. DOI 10.36948/ijfmr.2024.v06i05.27443
DOI	https://doi.org/10.36948/ijfmr.2024.v06i05.27443
Short DOI	https://doi.org/g4qmt4

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 5 Cover Page Vol 6 Isu 4 Cover Page Vol 6 Isu 3

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Reviewing The Latest Treatments for Haemophilia

Share this